X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with J.B.Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs J.B.CHEMICALS - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA J.B.CHEMICALS CIPLA/
J.B.CHEMICALS
 
P/E (TTM) x 45.7 15.1 302.7% View Chart
P/BV x 3.9 2.4 164.1% View Chart
Dividend Yield % 0.3 0.2 201.8%  

Financials

 CIPLA   J.B.CHEMICALS
EQUITY SHARE DATA
    CIPLA
Mar-17
J.B.CHEMICALS
Mar-16
CIPLA/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs622318 195.5%   
Low Rs458200 229.7%   
Sales per share (Unadj.) Rs181.9148.0 122.9%  
Earnings per share (Unadj.) Rs12.919.1 67.4%  
Cash flow per share (Unadj.) Rs29.323.9 122.4%  
Dividends per share (Unadj.) Rs2.000.50 400.0%  
Dividend yield (eoy) %0.40.2 191.7%  
Book value per share (Unadj.) Rs155.7128.9 120.7%  
Shares outstanding (eoy) m804.5184.82 948.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.7 169.8%   
Avg P/E ratio x42.013.6 309.5%  
P/CF ratio (eoy) x18.410.8 170.5%  
Price / Book Value ratio x3.52.0 172.8%  
Dividend payout %15.52.6 593.1%   
Avg Mkt Cap Rs m434,51621,951 1,979.4%   
No. of employees `00023.02.7 842.8%   
Total wages/salary Rs m26,3381,841 1,430.5%   
Avg. sales/employee Rs Th6,349.14,590.9 138.3%   
Avg. wages/employee Rs Th1,143.0673.4 169.7%   
Avg. net profit/employee Rs Th449.3592.1 75.9%   
INCOME DATA
Net Sales Rs m146,30212,551 1,165.6%  
Other income Rs m2,287542 422.2%   
Total revenues Rs m148,58913,093 1,134.9%   
Gross profit Rs m24,7582,055 1,204.9%  
Depreciation Rs m13,229412 3,207.9%   
Interest Rs m1,59496 1,665.4%   
Profit before tax Rs m12,2222,088 585.3%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,798469 383.2%   
Profit after tax Rs m10,3541,619 639.7%  
Gross profit margin %16.916.4 103.4%  
Effective tax rate %14.722.5 65.5%   
Net profit margin %7.112.9 54.9%  
BALANCE SHEET DATA
Current assets Rs m87,3707,778 1,123.4%   
Current liabilities Rs m33,0814,358 759.1%   
Net working cap to sales %37.127.2 136.2%  
Current ratio x2.61.8 148.0%  
Inventory Days Days8755 159.1%  
Debtors Days Days6280 77.9%  
Net fixed assets Rs m111,5675,713 1,953.0%   
Share capital Rs m1,609170 948.7%   
"Free" reserves Rs m123,64510,547 1,172.4%   
Net worth Rs m125,25410,937 1,145.2%   
Long term debt Rs m36,4540-   
Total assets Rs m209,53215,574 1,345.4%  
Interest coverage x8.722.8 38.0%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.70.8 86.6%   
Return on assets %5.711.0 51.8%  
Return on equity %8.314.8 55.9%  
Return on capital %8.520.0 42.6%  
Exports to sales %34.248.7 70.2%   
Imports to sales %8.37.1 117.8%   
Exports (fob) Rs m50,0506,115 818.5%   
Imports (cif) Rs m12,203889 1,373.1%   
Fx inflow Rs m51,0666,169 827.8%   
Fx outflow Rs m17,6781,285 1,375.6%   
Net fx Rs m33,3884,884 683.6%   
CASH FLOW
From Operations Rs m23,8241,397 1,705.7%  
From Investments Rs m-13,127-320 4,098.2%  
From Financial Activity Rs m-13,239-1,196 1,107.1%  
Net Cashflow Rs m-2,478-102 2,422.3%  

Share Holding

Indian Promoters % 16.0 55.4 28.9%  
Foreign collaborators % 20.8 0.3 6,933.3%  
Indian inst/Mut Fund % 12.2 3.4 359.9%  
FIIs % 23.7 3.9 607.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 37.0 70.8%  
Shareholders   161,166 30,437 529.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   WOCKHARDT LTD.  FULFORD INDIA  MERCK LTD  DIVIS LABORATORIES  UNICHEM LAB  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strong US Markets; SBI, Tata Steel & Other Top Cues to Sway the Markets Today(Pre-Open)

After opening the day in green, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 16, 2018 (Close)

TRACK CIPLA

CIPLA - PLETHICO PHARMA COMPARISON

COMPARE CIPLA WITH

MARKET STATS